Carvedilol versus Propranolol in Preventing Decompensation in Patients with Compensated Cirrhosis: A Real-World Propensity-Matched Study

Hussam Almasri; Muhammad Ali Butt; Rahul Karna; Guneet Sidhu; Himsikhar Khataniar; John T Bassett; Raza Malik; Ming Valerie Lin; Nabeeha Mohy-Ud-Din

doi:10.15403/jgld-6497

Authors

Hussam Almasri University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA https://orcid.org/0000-0002-9549-8352
Muhammad Ali Butt Beth Israel Lahey Health Inc., Cambridge, MA, USA
Rahul Karna University of Minnesota Twin Cities, Minneapolis, MN, USA
Guneet Sidhu University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA
Himsikhar Khataniar Allegheny Health Network Graduate Medical Education, Pittsburgh, PA, United States
John T Bassett Sanford Health, Fargo, ND, USA
Raza Malik Beth Israel Lahey Health Inc., Cambridge, MA, USA
Ming Valerie Lin Beth Israel Lahey Health Inc., Cambridge, MA, USA
Nabeeha Mohy-Ud-Din Allegheny Health Network Graduate Medical Education, Pittsburgh, PA, USA

DOI:

https://doi.org/10.15403/jgld-6497

Keywords:

compensated liver cirrhosis, Portal Hypertension, carvedilol, propranolol

Abstract

Background and Aims: Non-selective beta-blockers are widely used for the management of portal hypertension and prevention of variceal bleeding in patients with liver cirrhosis. While studies have demonstrated carvedilol‘s superiority in reducing portal pressure compared to propranolol, limited real-world data directly compare their efficacy in preventing decompensation.

Methods: We conducted a retrospective cohort study using the TriNetX database on patients from several healthcare organizations in the US Collaborative Network. Cohorts were defined as adult patients with compensated cirrhosis who were prescribed either carvedilol or propranolol. Propensity score matching was applied to balance demographic, clinical, and laboratory characteristics. The first decompensation event, all-cause hospitalization, and all-cause mortality were defined as outcomes.

Results: After matching, each cohort included 12,890 patients. The mean age was 59.6 years. Comorbidities and laboratory findings were well-balanced between the two groups. Patients receiving carvedilol had a significantly lower risk of developing new decompensating events within five years, including ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome. Spontaneous bacterial peritonitis was not significantly different between the groups. Post-matching analysis showed marginally reduced all-cause mortality in the carvedilol group at five years.

Conclusions: In this real-world study, carvedilol demonstrated superior efficacy compared with propranolol in reducing key decompensatory events in patients with compensated cirrhosis, likely due to its enhanced ability to lower portal pressure. However, the mortality benefit probably requires further studies to unfold.